Congressional Dems Generating Heat, But No Hearings, On Rx Prices
This article was originally published in The Pink Sheet Daily
Executive Summary
House oversight committee Democrats want to subpoena Valeant Pharmaceuticals and hold a hearing with Turing Pharmaceuticals on drug price increases. Their requests may have more impact on investors than committee leadership, as the company saw a same-day stock decrease of 16%.
You may also be interested in...
Senate's Bipartisan Rx Pricing Probe Seeks Documents Regarding FDA Regs
Probe launched by the Senate Aging panel asks four manufacturers – Valeant, Turing, Retrophin and Rodelis – for documents pertaining to pricing their products, but also wants to know how they may have analyzed FDA regs to help them avoid competition.
HHS Raises Profile In Drug Costs Discussion
On Nov. 20, HHS will host a day-long forum on pharmaceuticals, including a look at high-cost specialty drugs and innovative purchasing strategies.
PhRMA Takes Aim At Valeant In Defense Of Drug Pricing By ‘Innovative’ Firms
The strategy of publicly criticizing pharmaceutical companies, albeit non-members, is an unusual one for PhRMA. But it demonstrates the group’s interest in playing offense, and not just defense, in the drug price debate.